NMADNasdaqPharmaceutical PreparationsUS GAAP · USD

Lixte Biotechnology Holdings, Inc

NOMAD POWER SOLUTIONS, INC. is a U.S.-based clinical-stage biopharmaceutical company focused on developing cancer therapies built around protein phosphatase 2A (PP2A) inhibition. Its work centers on the lead compound LB-100 and related oncology drug-development activities, including clinical research, patent protection, and licensing arrangements.

Kysy yhtiöstä
Liikevoitto (EBIT)−5,1milj. USD
−43,0 %v/v
Nettotulos−6,1milj. USD
−69,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−8−6−4−20milj. USD2020: EBIT −3,3 milj. USD20202021: EBIT −6,7 milj. USD20212022: EBIT −6,3 milj. USD20222023: EBIT −5,1 milj. USD20232024: EBIT −3,6 milj. USD20242025: EBIT −5,1 milj. USD2025−5,1
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Lixte Biotechnology Holdings, Inc

Liiketoiminta

Osuus liikevaihdosta
Lead drug candidate development70 %

Development of LB-100 and related PP2A inhibitor oncology assets.

Clinical research programs20 %

Preclinical and clinical trial work supporting cancer drug development.

Licensing and royalty rights10 %

License agreements, sublicensing rights, and royalty-bearing arrangements.

Asiakkaat

The company’s direct counterparties are primarily pharmaceutical companies, clinical trial sites, research collaborators, and licensors rather than end-patient buyers. Its therapies are developed for oncology use, so eventual commercial customers would be healthcare providers, hospitals, and cancer treatment centers if products reach approval and market launch.

Pharmaceutical collaborators

Companies that may partner on development, trials, or commercialization of LB-100 and related assets.

Clinical trial sites

Hospitals and cancer centers that enroll patients and generate clinical data for regulatory filings.

Licensing counterparties

Organizations involved in license, sublicense, and royalty arrangements tied to the company’s IP.

Future oncology providers

Hospitals, cancer centers, and physicians that would use approved therapies in practice.

Strategia

The company’s strategy is to advance LB-100 through clinical development, generate supporting data, and pursue regulatory and commercialization pathways for oncology use. It also seeks to protect and extend value through patents, licensing, and potential collaborations with pharmaceutical companies and clinical sites.

Advance LB-100 clinical developmentLyhyt aikaväli

Clinical progress is the main path to value creation for a single-asset oncology company.

Secure additional capitalLyhyt aikaväli

Development-stage biopharma requires external funding to continue trials and development.

Build licensing and IP valueKeskipitkä aikaväli

Patent and license rights can support future commercialization and partnering economics.

Maantiede

The company is headquartered in Pasadena, California and operates as a U.S.-based development-stage business. Its disclosed licensing obligations are country-by-country, indicating that future commercialization and royalty exposure may extend across multiple approved markets rather than a single geography.

Riskit

The company faces the typical risks of a clinical-stage biopharmaceutical developer: trial failure, regulatory delay, and dependence on external funding. Because it has not yet generated revenue, its ability to continue operations depends on capital access, while licensing obligations and royalty commitments can affect future economics if commercialization occurs.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing risk1Clinical development risk2Regulatory risk3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company must raise additional capital to fund clinical development and operations.

    Kohdistuu: Corporate funding needs

  2. Clinical development riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    LB-100 may not show sufficient efficacy or safety in trials to support approval.

    Kohdistuu: Lead asset LB-100

  3. Regulatory riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Marketing approval depends on successful filings and regulator acceptance in each territory.

    Kohdistuu: Oncology approvals

  4. Intellectual property riskVaikutus: Keskitaso

    Patent scope, validity, and license terms affect exclusivity and commercialization value.

    Kohdistuu: Licensed PP2A inhibitor assets

  5. Royalty obligation riskVaikutus: Keskitaso

    Future sales or sublicensing revenue may be subject to NIH royalties and minimum payments.

    Kohdistuu: License agreement with NIH

Kysy Clarifolta: Lixte Biotechnology Holdings, Inc

Kirjanpito

Harkinnanvaraiset erät
Clinical trial accruals

Management estimates unpaid trial and development costs, which can shift period expense recognition.

Vaikutus: Research and development expense

Equity compensation valuation

Shares and options issued for services must be measured at fair value, affecting operating expense.

Vaikutus: General and administrative expense

License royalty commitments

Minimum annual royalties and earned royalties create future cash obligations and accruals.

Vaikutus: Other liabilities and cash outflows

Stock-based compensation

A substantial portion of compensation is paid in equity, affecting expense recognition and dilution.

Vaikutus: Operating expenses and share count

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Lisata Therapeutics, Inc

LSTA · Pharmaceutical Preparations

PharmaCyte Biotech, Inc.

PMCB · Biological Products, (No Diagnostic Substances)

LB Pharmaceuticals Inc

LBRX · Pharmaceutical Preparations

Lantern Pharma Inc.

LTRN · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTA · Pharmaceutical Preparations

Lipella Pharmaceuticals Inc.

LIPO · Pharmaceutical Preparations

Päivitetty: 24.9.2026